SCHEMBL4801786

SCHEMBL4801786

CC(=O)NC(=Cc1ccc(N)c(Cl)c1)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MCL1 Q07820 1/20 0.46
▸ RECQL P46063 2/20 0.43
▸ ITGB1 P05556 2/20 0.39
▸ ITGA4 P13612 2/20 0.39
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 6/20 0.37
▸ CYP3A4 P08684 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ THRB P10828 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ CASP1 P29466 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ HDAC3 O15379 1/20 0.33
▸ HDAC4 P56524 1/20 0.33
▸ HDAC1 Q13547 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4801779 1.00 MCL1 (0.46) MCL1RECQLITGB1ITGA4MAPT
SCHEMBL2165956 0.87 MCL1 (0.48) MCL1RECQLITGB1ITGA4MAPT
SCHEMBL2165961 0.87 MCL1 (0.48) MCL1RECQLITGB1ITGA4MAPT
SCHEMBL5230931 0.86 ALDH1A1 (0.40) MCL1RECQLMAPTALDH1A1HPGD
SCHEMBL3093807 0.84 MCL1 (0.47) MCL1RECQLITGB1ITGA4MAPT
SCHEMBL3093825 0.84 MCL1 (0.47) MCL1RECQLITGB1ITGA4MAPT
SCHEMBL3093817 0.84 MCL1 (0.47) MCL1RECQLITGB1ITGA4MAPT
SCHEMBL6502129 0.82 MEN1 (0.39) MCL1RECQLMAPTALDH1A1POLB
SCHEMBL6502128 0.82 MEN1 (0.39) MCL1RECQLMAPTALDH1A1POLB
SCHEMBL6501024 0.82 MEN1 (0.39) MCL1RECQLMAPTALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7439237-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-10-21 — — US disclosed
US-20070238715-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-10-11 — — US disclosed
US-20050282857-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-12-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238715-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA MCL1 4556/4885RECQL 756/4885ITGB1 3207/4885
US-20050282857-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA MCL1 4556/4885RECQL 756/4885ITGB1 3207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback